Dosage Appropriacy Evaluation of Oral Venlafaxine Related to CYP2D6 Genotype Using Physiologically Based Pharmacokinetic (PBPK) Model

被引：0
|
作者：
Cho, Changkeun [1 ]
机构：
[1] Sungkyunkwan Univ, Seoul, South Korea
来源：
FASEB JOURNAL | 2020年 / 34卷
关键词：
D O I：
10.1096/fasebj.2020.34.s1.03769
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Physiologically based pharmacokinetic modelling to predict the pharmacokinetics of metoprolol in different CYP2D6 genotypes
    Lee, Choong-Min
    Kang, Pureum
    Cho, Chang-Keun
    Park, Hye-Jung
    Lee, Yun Jeong
    Bae, Jung-Woo
    Choi, Chang-Ik
    Kim, Hyung Sik
    Jang, Choon-Gon
    Lee, Seok-Yong
    ARCHIVES OF PHARMACAL RESEARCH, 2022, 45 (06) : 433 - 445
  • [22] Effect of CYP2D6 genotype on pharmacokinetic interactions with psychotropic drugs
    Yasui-Furukori, N
    Tateishi, T
    Kondo, T
    Mihara, K
    Suzuki, A
    Ono, S
    Kaneko, S
    PHARMACOGENETICS - TAILOR-MADE PHARMACOTHERAPY, 2002, 1244 : 21 - 31
  • [23] CYP2B6 GENOTYPE AFFECTS METHADONE DISPOSITION IN CHILDREN AS DEMONSTRATED BY PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING.
    Gerhart, J.
    Edginton, A.
    Watt, K.
    Cohen-Wolkowiez, M.
    Harper, B.
    Muller, W.
    Delmore, P.
    Atz, A.
    Payne, E.
    Erinjeri, J.
    Lin, S.
    Gonzalez, D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S15 - S15
  • [24] Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors
    Gressier, F.
    Verstuyft, C.
    Hardy, P.
    Becquemont, L.
    Corruble, E.
    JOURNAL OF NEURAL TRANSMISSION, 2015, 122 (01) : 35 - 42
  • [25] Evaluation of the Effect of CYP2D6 Genotypes on Tramadol and O-Desmethyltramadol Pharmacokinetic Profiles in a Korean Population Using Physiologically-Based Pharmacokinetic Modeling
    Jeong, Hyeon-Cheol
    Bae, Soo Hyeon
    Bae, Jung-Woo
    Lee, Sooyeun
    Kim, Anhye
    Jang, Yoojeong
    Shin, Kwang-Hee
    PHARMACEUTICS, 2019, 11 (11)
  • [26] Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors
    F. Gressier
    C. Verstuyft
    P. Hardy
    L. Becquemont
    E. Corruble
    Journal of Neural Transmission, 2015, 122 : 35 - 42
  • [27] Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers
    Fukuda, T
    Yamamoto, I
    Nishida, Y
    Zhou, Q
    Ohno, M
    Takada, K
    Azuma, J
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 47 (04) : 450 - 453
  • [28] CYP2B6 GENOTYPE AFFECTS METHADONE DISPOSITION IN CHILDREN AS DEMONSTRATED BY PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING.
    Gerhart, J.
    Edginton, A.
    Watt, K.
    Cohen-Wolkowiez, M.
    Harper, B.
    Muller, W.
    Delmore, P.
    Atz, A.
    Payne, E.
    Erinjeri, J.
    Lin, S.
    Gonzalez, D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S64 - S64
  • [29] Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach
    Kneller, Lisa Alina
    Zubiaur, Pablo
    Koller, Dora
    Abad-Santos, Francisco
    Hempel, Georg
    CLINICAL PHARMACOKINETICS, 2021, 60 (12) : 1569 - 1582
  • [30] Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach
    Lisa Alina Kneller
    Pablo Zubiaur
    Dora Koller
    Francisco Abad-Santos
    Georg Hempel
    Clinical Pharmacokinetics, 2021, 60 : 1569 - 1582
12345